| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 11, 2026, by and between Vor Biopharma Inc., a Delaware corporation (the “Company”), and RemeGen Co., Ltd. (the “Investor”). |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 |
Form 4: Sokolove Jeremy Brett, Chief Medical Officer
Gave up 1,917 shares to cover exercise price or tax ($36.9K) |
| 30 Oct 2026 | 424B5 |
| 30 Oct 2026 | 10-Q |
| 05 Oct 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others
Received 500 shares by exercise or conversion ($6.4K) |
| 04 Sep 2026 | S-3ASR |
| 26 Aug 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others
Received 1,500 shares by exercise or conversion ($5.6K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 10-Q |
| 07 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | SCHEDULE 13G |
| 30 Jul 2026 | SCHEDULE 13G |
| 21 Jul 2026 | SCHEDULE 13D/A |
| 21 Jul 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others
Received 2,100,000 shares by exercise ($4.2K) · Sold 213 shares ($4.21K) |
| 09 Jul 2026 |
Form 3: Zaccardelli David, Director
No securities owned |
| 09 Jul 2026 |
Form 4: Zaccardelli David, Director
Granted 42,658 Stock Option (Right to Buy) |
Loading...